A comparative study of 11 European countries found a rapid uptake of novel T2D medicines such as incretin-based therapy (glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) and sodium-glucose cotransporter (SGLT-2) inhibitors, suggesting an increase in the prescribing policy and prioritizing diabetes care as a healthcare priority [5]. Here, DPP4 is linked to type 2 diabetes mellitus.